Navigation Links
Abiant, Inc. Announces Close on Investment Round
Date:10/1/2007

CHICAGO, Oct. 1 /PRNewswire/ -- Abiant, Inc., an Illinois based company specializing advanced bio-imaging to accelerate and improve drug development and disease diagnosis, announces the successful closing of a $600,000 private placement. Lead investor Heartland Angels, an angel network specializing in early-stage technology, syndicated the round with Kettering Medical Center and other participants. Abiant has developed partnerships with large pharmaceutical companies and with academic collaborators. The company has obtained an exclusive license from New York University School of Medicine to image processing technology that has enabled the early and accurate identification of dementias.

Ed Maier, owner of the Maier Consulting Group and a former Senior Partner with Arthur Andersen, and Rick Mace, Vice President, Clinical Services Division of Kettering Medical Center, have joined Abiant's Board of Directors as part of this Offering. We are excited about supporting a technology that will change the way we monitor CNS drug effects in the clinical testing process", said Ron Kirschner, M.D., President of Heartland Angels. Dawn Matthews, President and CEO of Abiant, said "With this financing, we are adding two valuable strategic partners and the resources to expand the application of our imaging technology. We are eager to continue the progress created by the dedication and shared vision of our team, customers, and stakeholders." O.B. Parrish, Chairman of Abiant's Board, added "This financing provides Abiant with the opportunity to grow and capitalize on its technology".

About Abiant, Inc.

Abiant, Inc. uses proprietary image analysis methods and software to provide a sensitive biomarker of drug effects and disease progression. The imaging information, which includes biochemical, functional, and structural measurements, can be used to accelerate or reduce risk of decision making in both drug development and disease treatment. The Company's focus area
'/>"/>

SOURCE Abiant, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... The Formulate Fusion Fabric Display ... and marketing teams looking for a fully-functional package for their ... “everything you’ll need to put together a stunning and eye-catching ... a number of displays and accessories that can be quickly ... 20 feet in size. These components vary from kit to ...
(Date:5/20/2013)... -- , Collaboration with the U.S. ... in treatment of mastitis , Major ... begin in the second half 2013 ... Limited (ASX: POH, OTCQX: PPGNY) will collaborate with ... (ARS) to develop and trial products targeting the serious ...
(Date:5/20/2013)... Pa (PRWEB) May 20, 2013 Oven ... with ramp/soak capabilities. The 5R6-900 benchtop controller has ... the device can be plugged into the wall as ... power supply. This distinctive detail makes the device unique, ... , The laboratory temperature controller can also be used ...
(Date:5/20/2013)... -- Today, at the American Psychiatric Association (APA) Meeting ... James McGough , M.D., M.S., principal investigator and ... Neuroscience and Human Behavior and David Geffen ... California Los Angeles (UCLA), and director of clinical teaching ... at UCLA, presented the results of a Phase I ...
Breaking Biology Technology:GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Phosphagenics Signs Research Agreement with the Agricultural Research Service 2New Laboratory Temperature Controller by Oven Industries 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5
... People Living with ... Fibromyalgia -, INDIANAPOLIS, Oct. ... Martha Beck, one day became a seemingly,endless cycle of widespread pain, fatigue, ... answer to the painful,symptoms she was experiencing before she finally received a ...
... Data on Ceftaroline, a Novel, Broad-Spectrum Cephalosporin in,Development ... and,Community Acquired Pneumonia (CAP), WASHINGTON, Oct. 27, ... presented a detailed analysis of CANVAS I, a,globally ... 48th,Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ...
... Today to ... Discuss Results, BIRMINGHAM, ... announced results of an,exploratory Phase 2 trial of intravenous (i.v.) peramivir, ... The Phase 2 trial compared the efficacy and,safety of five days ...
Cached Biology Technology:From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 2From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 3From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 4From Pain to Unexpected Fame: One Woman's Journey to Know Fibro 5Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 2Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 3Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 4Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 5Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 6Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 7Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 8BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 2BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 3BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 4BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 6
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
(Date:5/20/2013)... Minnesota Medical School researchers from the Masonic Cancer Center, ... Tumor Program, have developed a new mouse model of ... to discover new genes and gene pathways driving this ... week in the journal Nature Genetics . , ... lab of David Largaespada, Ph.D., professor in the Medical ...
(Date:5/20/2013)... DIEGO (May 20, 2013) - A novel ... headline the groundbreaking research that will be unveiled at ... Conference (NBC). The meeting takes place Monday, May 20 ... Hotel and Marina. , "The main goal of ... fight against a pathogen that causes the disease", explained ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4U of M researchers develop model for better testing, targeting of MPNST 2Germ-fighting vaccine system makes great strides in delivery 2
... parts of the shark and are often removed from the body, ... practice, many countries allow the fins to be landed detached from ... per cent of the total shark catch. New University of British ... A study published this week in the journal ...
... to their doctor for a blood test generally has to ... of uncertainty can make patients anxious especially in critical ... it takes so long for laboratories to analyze samples is ... Each sample must be accompanied by meticulous records, so lab ...
... Md. (March 1, 2012)The American Physiology Society (APS) has announced ... experimental animals and the sex or gender of humans used ... 13 peer-reviewed journals. This notable requirement for all research study ... be presented in an editorial, " In Pursuit of Scientific ...
Cached Biology News:Law that regulates shark fishery is too liberal: UBC study 2'Labor der Zukunft' -- Tomorrow's laboratory technology 2'Labor der Zukunft' -- Tomorrow's laboratory technology 3APS issues new policy requiring identification of sex or gender in reporting scientific research 2APS issues new policy requiring identification of sex or gender in reporting scientific research 3
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: